Clinical Trials Logo
  1. Home
  2. Histiocytosis
  3. NCT03127709

A Study of Memory, Thinking, and Brain Imaging in Adults With Histiocytosis

Histiocytosis Clinical Trial

Official title:
A Clinical, Structural, and Functional Neuroimaging Study of Cognition in Adults With Erdheim-Chester Disease, Langerhans Cell Histiocytosis, Rosai-Dorfman Disease, and Other Histiocytoses

Clinical Trial Summary

The purpose of this study is to try to understand how histopcytosis can cause symptoms or problems in the brain. The tests being done in the study will look at memory and thinking as well as brain function via MRI scan.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03127709
Study type Observational
Source Memorial Sloan Kettering Cancer Center
Contact
Status Active, not recruiting
Phase
Start date April 7, 2017
Completion date April 2025
View Details
See also
  Status Clinical Trial Phase
Completed NCT01049854 - CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant Phase 2
Recruiting NCT05915208 - Histiocytic Disorder Follow-up Study
Recruiting NCT04437381 - Molecular Targets for the Treatment of Histiocytosis
Terminated NCT01050439 - Unrelated Donor Transplant for Malignant and Non-Malignant Disorders Phase 2
Active, not recruiting NCT00145626 - HLA-Nonidentical Stem Cell and Natural Killer Cell Transplantation for Children Less the Two Years of Age With Hematologic Malignancies Phase 2
Not yet recruiting NCT05803629 - Characterizing Histiocytosis With 68Ga-FAPI PET/CT N/A
Recruiting NCT04665674 - Adult Pulmonary Langerhans Cell Histiocytosis: a National Registry-based Prospective Cohort Study
Terminated NCT02012231 - Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers. Phase 1
Completed NCT01225718 - Ceftriaxone in Non-neutropenic Fever N/A
Recruiting NCT05786924 - A Study of BDTX-4933 in Patients With KRAS, BRAF and Select RAS/MAPK Mutation-Positive Cancers Phase 1
Recruiting NCT04943198 - Optimization of the Time and Dosage of Vemurafenib in BRAF Positive Juvenile Patients With Refractory Histiocytosis Phase 2
Recruiting NCT04943211 - Determination of Molecular Status, the Efficacy and Safety of Fluorodeoxyglucose in PET-CT Imaging Phase 3
Recruiting NCT04943224 - Optimization of the Time and Dosage of Trametinib in BRAF Negative Juvenile Patients Phase 2